SOURCE: Goldman Small Cap Research, Inc.

June 13, 2013 09:05 ET

Plandai Biotechnology Positions Itself in War Against Cholesterol

BALTIMORE, MD--(Marketwired - Jun 13, 2013) -  Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, reports that recent cholesterol study participants who consumed high amounts of green tea had reduced levels of "bad" cholesterol, which is a major positive for Plandaí Biotechnology Inc. (OTCQB: PLPL). 

The relationship between high cholesterol levels and potential heart issues prompted a number of studies targeting the reduction of bad cholesterol, including those using green tea. Considering the higher bioavailability of the Plandaí offerings, there will likely be future trials using Plandaí's products in order to maximize consumption and efficacy of the key catechins. Plandaí develops highly bioavailable, phytonutrient rich extracts that include known anti-oxidants, such as EGCG found in green tea, which it plans to utilize to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions.

Recently published studies have indicated that groups who consumed high amounts of green tea had reduced levels of "bad" cholesterol. For example, one study which ran 20 trials spanning anywhere from 3 to 20 weeks, showed a marked reduction in low-density lipoprotein (LDL) levels (i.e. bad cholesterol). Specifically, the participants showed a five to six point reduction in their levels. The common denominator in both trials is the correlation between green tea consumption and cholesterol reduction, along with overall wellness. Green tea contains catechin polyphenols, specifically the powerful antioxidant, epigallocatechin gallate (EGCG). Unfortunately, green tea polyphenols, including EGCG, are notorious for their low bioavailability or ability to be absorbed into the blood stream, but that could change with Plandai's offerings.

Considering that Plandaí offers Phytofare™ Catechin Complex, which is processed to deliver a natural, antioxidant-rich product that contains the full range of green tea catechins at a bioavailability level many times that of other products available on the market, the Company's flagship product could emerge as consumers' cholesterol lowering product of choice.

Goldman Small Cap Research articles and reports on Plandai as well as associated disclaimers can be accessed or downloaded in their entirety by visiting

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit

A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit

About Plandai Biotechnology, Inc. (OTCQB: PLPL): Plandai Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts, which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandai Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing the patented Phytofare™ extracts in-house allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include food and beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit

Contact Information